Janin Chandra
Janin received her Master of Science in Germany, and completed her PhD studies at the University of Zurich in Switzerland. In 2012, Janin joined Prof. Ian Frazer's research team at the University of Queensland (UQ), where she investigated the role of different types of professional antigen-presenting cells in the development of squamous cell carcinomas and its associated immune suppression. In 2015, Janin joined the biotech company Admedus Vaccines Pty Ltd, where, as Senior Scientist, she developed immunotherapeutic vaccine strategies for the treatment of herpes-simplex 2 infections and HPV-mediated cancers, and progressed these into clinical trials. In 2019, Janin re-joined UQ and continued her research interest in antigen-presenting cells modulation in cutaneous and mucosal squamous cell carcinomas, with the aim to develop new therapeutic strategies to enhance immune effector responses.
Abstracts this author is presenting:
